CLS B.ST Stock Analysis
CL
Uncovered
Clinical Laserthermia Systems AB is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Clinical Laserthermia Systems AB engages in the development and manufacture of pharmaceutical products. The company is headquartered in Lund, Skane. The company went IPO on 2009-04-16. The firm develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The firm's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.